Peter D Sasieni

Nov 18, 2024 | nature.com | Peter D Sasieni

Correction to: British Journal of Cancer https://doi.org/10.1038/s41416-023-02243-9, published online 25 April 2023Following publication of the article, the authors noticed errors in the model code on re-examination. Data has been corrected in Tables 1, 2, 3 and 4 in the main article; Tables S4A and S4B in the supplementary material have also been updated.

Aug 22, 2024 | bmj.com | Peter D Sasieni |Richard Neal |Charles Swanton

Dear EditorThe BMJ Investigation relating to the NHS-Galleri Trial(1) raises important public health issues but is inaccurate. Of concern is the view that the trial is unethical. The trial was judged ethical by the Health Research Authority (Wales Research Ethics Committee 1: 21/WA/0141). This was not stated in the article. The claim that the trial is unethical is damaging to the conduct of the trial and was repeated on social media and in national press headlines.

Oct 17, 2023 | nature.com | Harry Hill |Nora Pashayan |Peter D Sasieni

AbstractThere has been growing interest in the UK and internationally of risk-stratified breast screening whereby individualised risk assessment may inform screening frequency, starting age, screening instrument used, or even decisions not to screen. This study evaluates the cost-effectiveness of eight proposals for risk-stratified screening regimens compared to both the current UK screening programme and no national screening.

Apr 25, 2023 | nature.com | Peter D Sasieni

AbstractBackgroundScreening programmes utilising blood-based multi-cancer early detection (MCED) tests, which can detect a shared cancer signal from any site in the body with a single, low false-positive rate, could reduce cancer burden through early diagnosis. MethodsA natural history (‘interception’) model of cancer was previously used to characterise potential benefits of MCED screening (based on published performance of an MCED test).